Stratified Prognostic Comparison Between Stage IIB-IVA Cervical Adenocarcinoma and Squamous Cell Carcinoma: A SEER Database-Based Study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Prognosis for cervical adenocarcinoma is often worse than squamous cell carcinoma. However, treatment and stage significantly impact survival, with some advanced stages showing no difference by tumor type when treated with chemoradiation.
Area Of Science
- Gynecologic Oncology
- Radiation Oncology
- Medical Oncology
Background
- Cervical cancer prognosis differs between adenocarcinoma and squamous cell carcinoma.
- Existing studies lack detailed staging and grouping for comparative prognosis.
Purpose Of The Study
- To compare the prognosis of cervical adenocarcinoma and squamous cell carcinoma.
- To analyze the impact of stage and treatment on survival outcomes.
Main Methods
- Utilized SEER database for Stage IIB-IVA patients (2000-2019).
- Applied propensity score matching (PSM) to control for confounding factors.
- Kaplan-Meier curves and log-rank tests analyzed overall survival (OS) and cancer-specific survival (CSS).
Main Results
- Treatment method significantly correlated with prognosis (P<0.05).
- For radiotherapy or no treatment, OS/CSS depended on stage, not tumor type.
- In chemoradiation, Stage IIIA/IVA OS/CSS and Stage IIB OS were independent of histological type after PSM.
Conclusions
- Treatment and stage are key determinants of cervical cancer survival.
- For specific treatment regimens (chemoradiation), histological type may not significantly alter prognosis in advanced stages.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...